R&D
Technology to Increase Selectivity for
cancer cells and Enhance Efficacy
Business Performance
  • HOME
  • R&D
  • Business Performance
Technology Transfer and Collaboration
  • Aptamer sciences
  • 안국약품
  • bridgebio
  • 산업통상자원부
  • aptamer group
  • proen
Strategic Investments
  • aston sci
  • aston sci
  • aston sci
  • aston sci
Government Research Grant
  • aston sci
    ADC technology development
  • aston sci
    ADC anticancer drug development
  • aston sci
    ADC linker technology development

Presentations

Product The name of the society Title Content Date Presentation Materials
NTX-301 ASH 2021 A Study on The Preclinical Efficacy, Underlying Mechanisms, and Sensitivity Markers of A Novel Hypomethylating Agent NTX-301 in Acute Myeloid Leukemia Identification of safety for humans, co-administration potential, efficacy indicators, and biomarkers Dec. 2021
NTX-301 ASCO 2021 Phase I Trial of 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors Identification of safety for humans, oral administration potential, target engagement, and efficacy indicators Jun. 2021